Guihua Wang
ORCID: 0000-0001-5423-9357Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.”.
Yunpeng Yang, Jian-ji Pan, Xiaozhong Chen, Yan Sun, Hui Wang +13 more
Guihua Wang, Chien‐Feng Li, Xian Zhang, Zhen Cai, Tingjin Chen +16 more
Xian Zhang, Guihua Wang, Weina Zhang, Zhen Cai, Bo‐Syong Pan +17 more